The findings from the trial may also benefit patients with other cancers linked to BRCA mutations, such as ovarian, prostate, and pancreatic cancers.

The trial introduced a novel approach by incorporating a 48-hour gap between chemotherapy and Olaparib, allowing for better recovery and increasing the susceptibility of tumor cells to treatment.

Olaparib is a targeted treatment for cancers with BRCA gene mutations, working by blocking PARP, a molecule that helps cancer cells repair their DNA, leading to cell death.

Cancer Research UK emphasized the need for further studies to confirm the safety and effectiveness of this new treatment method.

After six years, Bochoven is cancer-free and credits the treatment for her recovery, emphasizing a new perspective on life post-cancer.

In contrast, the control group that received only chemotherapy had an 88% survival rate, with nine relapses and six deaths.

Jackie Van Bochoven, diagnosed with an aggressive breast tumor in 2019, participated in a clinical trial that combined chemotherapy with Olaparib before surgery.

The Cambridge-led trial included 39 patients who received chemotherapy followed by Olaparib, resulting in a remarkable 100% survival rate during the three years post-surgery, with only one relapse.

Professor Jean Abraham, the trial lead, expressed excitement over the 100% survival rate, which is rare for aggressive cancers, while emphasizing the need for further validation in larger studies.

Despite the small size of the trial, Associate Professor Theresa Hickey found the results promising for treating aggressive breast cancers, particularly those with BRCA mutations.

Olaparib was added to Australia's Pharmaceutical Benefits Scheme in 2024, making it more affordable and accessible for patients.

Mark O’Connor from AstraZeneca highlighted the potential of the trial results to transform treatment outcomes for patients with BRCA-related cancers.